Skip to main content



COVIDENCE UK May 2024 webinar: The Impact of Time Since Vaccination on Asthma Exacerbations and COVID-19 Severity.


COVIDENCE UK April 2024 webinar:  How does time since vaccination affect severity and duration of symptoms?


COVIDENCE UK March 2024 webinar: Recommended composition of influenza virus vaccines for use in the 2024 southern hemisphere influenza season


COVIDENCE UK February 2024 webinar: Undervaccination and severe COVID-19 outcomes


COVIDENCE UK January 2024 webinar: Discussing recent papers on long-COVID


COVIDENCE UK December 2023 webinar: Sleep after COVID-19


COVIDENCE UK November 2023 webinar:  Giulia Vivaldi on the long-term symptoms of COVID-19 and other acute respiratory infections


COVIDENCE UK October 2023 webinar: Is poor sleep a risk factor for long-COVID?


COVIDENCE UK September 2023 webinar: Long COVID research opportunity at Sano Genetics


COVIDENCE UK August 2023 webinar: Long-term symptom profiles after COVID-19 vs other acute respiratory infections


COVIDENCE UK July 2023 webinar: Sleep and breathlessness in long COVID


COVIDENCE UK June 2023 webinar: Is long COVID associated with viral persistence?


COVIDENCE UK May 2023 webinar: Air pollution exposure as a risk factor of COVID-19?


COVIDENCE UK April 2023 webinar: ‘A new drug for long-COVID? Clinical trial results presented at ECCMID 2023’


COVIDENCE  UK March 2023 webinar: How symptoms differ according to time since infection.


COVIDENCE UK February 2023 webinar: Symptom patterns in people who had COVID-19 vs those who didn't.


COVIDENCE UK January 2023 webinar: Persistent symptoms after COVID-19.


COVIDENCE UK December 2022 webinar: Long COVID - The therapeutic landscape.


COVIDENCE UK November 2022 webinar: Profile of people reporting long COVID.


COVIDENCE UK October 2022 webinar: Risk factors for persistent breathlessness after COVID-19.


COVIDENCE UK September 2022 webinar: impacts of air pollution on risk of COVID-19.


COVIDENCE UK August 2022 webinar: Impacts of lifting coronavirus restrictions.


COVIDENCE UK July 2022 webinar: Future directions for our work.


COVIDENCE UK June 2022 webinar: Our top 10 most important discoveries from the last 12 months.


COVIDENCE UK May 2022 webinar: Does Omicron trigger asthma attacks?


COVIDENCE UK April 2022 webinar: CORONAVIT trial results.


COVIDENCE UK March 2022 webinar: Poverty and the pandemic.


COVIDENCE UK February 2022 webinar: Which booster works best?


COVIDENCE UK January 2022 webinar: On post-vaccination COVID-19 or breakthrough disease.


COVIDENCE UK December 2021 webinar: How we have used your data to enhance scientific understanding of COVID-19 over the last year.


COVIDENCE UK November 2021 webinar: How post-vaccination symptoms relate to antibody response.


COVIDENCE UK September 2021 webinar: Final results from our pre-vaccination antibody study.


COVIDENCE UK August 2021 webinar: Early results from the post-vaccination antibody study and what we can learn about COVID-19 from genetic studies.


COVIDENCE UK June 2021 webinar: Findings of a new analysis looking at risk factors for symptoms following COVID-19 vaccination.


COVIDENCE UK May 2021 webinar: A summary of progress in our first year, and spells out the value of your participation, past and future.


COVIDENCE UK April 2021 webinar: Key findings from our new paper, “Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK)”.


COVIDENCE UK March 2021 webinar: Common queries about antibody tests and vaccine responses.


COVIDENCE UK February 2021 webinar: Updates on antibody study.


COVIDENCE UK December 2020 webinar: Brief 6-minute summary on our latest prospective analysis findings.


COVIDENCE UK November 2020 webinar: Rapid update.


COVIDENCE UK September 2020 webinar: In depth update on our latest findings.


COVIDENCE UK July 2020 webinar: The possibility of a second wave, impacts on mental health due to COVID-19, and long term symptoms of COVID-19.


COVIDENCE UK June 2020: First webinar about our progress and early findings.

Back to top